TCIM
GNCA

TIAA CREF Investment Management’s Genocea Biosciences, Inc. GNCA Stock Holding History

TIAA CREF Investment Management’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-32,984
Closed -$277K – 3172
2018
Q1 		$277K Buy
32,984
+19,975
+154% +$166K ﹤0.01% 2919
2017
Q4 		$121K Buy
13,009
+3,086
+31% +$31K ﹤0.01% 3034
2017
Q3 		$116K Buy
9,923
+238
+2% +$9.03K ﹤0.01% 3064
2017
Q2 		$404K Buy
+9,685
New +$466K ﹤0.01% 2956
2016
Q2 		– Sell
-8,011
Closed -$496K – 3224
2016
Q1 		$496K Sell
8,011
-9,363
-54% -$297K ﹤0.01% 2790
2015
Q4 		$732K Buy
17,374
+5,706
+49% +$272K ﹤0.01% 2758
2015
Q3 		$639K Buy
11,668
+4,049
+53% +$402K ﹤0.01% 2808
2015
Q2 		$837K Buy
7,619
+5,796
+318% +$538K ﹤0.01% 2781
2015
Q1 		$173K Hold
1,823
– – ﹤0.01% 3069
2014
Q4 		$102K Sell
1,823
-97
-5% -$6.63K ﹤0.01% 3117
2014
Q3 		$139K Hold
1,920
– – ﹤0.01% 3098
2014
Q2 		$288K Buy
1,920
+1,391
+263% +$211K ﹤0.01% 3069
2014
Q1 		$77K Buy
+529
New +$64.8K ﹤0.01% 3112

Other funds holding GNCA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TIAA CREF Investment Management's GNCA Position: Q2 2018 in Review

TIAA CREF Investment Management sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2018, closing a stake of 32,984 shares — an estimated $277K sold.

TIAA CREF Investment Management first reported a position in GNCA in Q1 2014 and held it in 13 quarters. The position peaked at $837K in Q2 2015. 54 funds tracked by Wall St. Rank hold GNCA as of Q2 2018.

  • TIAA CREF Investment Management reported no remaining Genocea Biosciences, Inc. position as of Q2 2018 after selling out during the quarter.
  • TIAA CREF Investment Management sold 32,984 Genocea Biosciences, Inc. shares in Q2 2018, an estimated $277K.
  • TIAA CREF Investment Management first reported a position in Genocea Biosciences, Inc. in Q1 2014 and held it in 13 quarters.
  • TIAA CREF Investment Management's Genocea Biosciences, Inc. position peaked at $837K in Q2 2015.
  • 54 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2018.

Based on TIAA CREF Investment Management's 13F filing for Q2 2018, filed 14 Aug 2018.